EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Re-evaluating hereditary breast and ovarian cancer risk: clinical impact of updated multigene panel sequencing and genetic counseling

Julie Isabelle Plougmann Gislinge, Anna Byrjalsen, Klara Vinsand Naver, Helle Vibeke Clausen, Pernille Ravn, Kresten Rubeck Petersen, Karin A W Wadt

Familial Cancer · 27.03.2026 · 25 (2)

DOI: 10.1007/s10689-026-00547-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Familial Cancer, online erschienen am 27.03.2026. Verfasst von Julie Isabelle Plougmann Gislinge und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Obstetrics and Fertility, Copenhagen University Hospital Herlev, Borgmester Ib Juuls Vej 1, 2730, Herlev, Denmark. Hauptthemen laut MEDLINE: Genetic Counseling, Genetic Testing, Genetic Predisposition to Disease, Ovarian Neoplasms. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An increased lifetime risk of ovarian cancer is observed among women with a family history of ovarian cancer, with or without breast cancer, as well as among carriers of pathogenic germline variants in ovarian cancer (OC) predisposition genes. Over the past two decades, additional OC–associated genes beyond BRCA1/2 have been identified, highlighting the need for updated genetic evaluation in women previously classified as high-risk without a known PV to ensure correct diagnosis and prevent overtreatment. This retrospective, quality assurance cohort study aimed to evaluate whether updated multigene panel sequencing and genetic counseling improve risk stratification. All women enrolled in the OC surveillance program at Copenhagen University Hospital Herlev between 2018 and 2023 and received counseling prior to the implementation of the revised 2017 guidelines in Denmark, were included. Among 674 women (median age 40.9), 174 had a BRCA1 PV, 168 had a BRCA2 PV, 55 had PVs in moderate-risk genes, and 277 were enrolled based on family history of OC ± BC alone. Of these 277, 216 (78%) underwent updated genetic testing and counselling; 165 (76%) had no increased risk of OC and were released from gynecological surveillance. Over a mean follow-up of 48 months, none developed OC, and one developed BC, corresponding to a negative predictive value of 99% for the updated risk assessment. Updated genetic testing and counseling significantly improve risk stratification in women previously classified as increased risk of OC based solely on family history. This supports re-evaluation of at-risk women and families to guide appropriate surveillance, reduce unnecessary follow-up and interventions, and align clinical practice with evolving guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic CounselingGenetic TestingGenetic Predisposition to DiseaseOvarian NeoplasmsBreast NeoplasmsHereditary Breast and Ovarian Cancer SyndromeHumansFemaleAdultMiddle AgedRetrospective StudiesRisk AssessmentDenmarkBRCA2 ProteinGerm-Line MutationBRCA1 ProteinAged

Stichwörter der Autor:innen

Breast cancerHereditaryNext-generation sequencingOvarian cancerPathogenic variantSurveillance

Substanzen

BRCA2 ProteinBRCA2 protein, humanBRCA1 Protein

Autor:innen und Institutionen

  • Department of Gynecology, Obstetrics and Fertility, Copenhagen University Hospital Herlev, Borgmester Ib Juuls Vej 1, 2730, Herlev, Denmark.
  • Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.
  • Department of Gynecology, Obstetrics and Fertility, University of Southern Denmark Odense Hospital, J. B. Winsløws Vej 4, 5000, Odense, Denmark.
  • Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark. Karin.wadt@regionh.dk.

Förderung

  • National Hospital

Zitieren

APA

Gislinge, J. I. P., Byrjalsen, A., Naver, K. V., Clausen, H. V., Ravn, P., Petersen, K. R., & Wadt, K. A. W. (2026). Re-evaluating hereditary breast and ovarian cancer risk: clinical impact of updated multigene panel sequencing and genetic counseling. Familial Cancer, 25(2). https://doi.org/10.1007/s10689-026-00547-2

Vancouver

Gislinge JIP, Byrjalsen A, Naver KV, Clausen HV, Ravn P, Petersen KR, et al. Re-evaluating hereditary breast and ovarian cancer risk: clinical impact of updated multigene panel sequencing and genetic counseling. Familial Cancer. 2026;25(2). doi:10.1007/s10689-026-00547-2

BibTeX
@article{Gislinge2026,
  author = {Gislinge, Julie Isabelle Plougmann and Byrjalsen, Anna and Naver, Klara Vinsand and Clausen, Helle Vibeke and Ravn, Pernille and Petersen, Kresten Rubeck and Wadt, Karin A W},
  title = {Re-evaluating hereditary breast and ovarian cancer risk: clinical impact of updated multigene panel sequencing and genetic counseling},
  journal = {Familial Cancer},
  year = {2026},
  volume = {25},
  number = {2},
  doi = {10.1007/s10689-026-00547-2}
}
Kostenlos starten →